Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MVA-Muc1-IL2: Completed Phase IIb enrollment

In May, Transgene completed enrollment of 140 patients

Read the full 88 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE